BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 20392816)

  • 1. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
    Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
    J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
    East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
    Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
    Yatomi Y
    Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.
    Pamuklar Z; Federico L; Liu S; Umezu-Goto M; Dong A; Panchatcharam M; Fulkerson Z; Berdyshev E; Natarajan V; Fang X; van Meeteren LA; Moolenaar WH; Mills GB; Morris AJ; Smyth SS
    J Biol Chem; 2009 Mar; 284(11):7385-94. PubMed ID: 19139100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
    J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin.
    Block RC; Duff R; Lawrence P; Kakinami L; Brenna JT; Shearer GC; Meednu N; Mousa S; Friedman A; Harris WS; Larson M; Georas S
    Prostaglandins Leukot Essent Fatty Acids; 2010; 82(2-3):87-95. PubMed ID: 20106646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
    Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
    J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of inhibitory actions of flavonols and related substances on lysophospholipase d activity of serum autotaxin by a convenient assay using a chromogenic substrate.
    Ueda K; Yoshihara M; Nakao M; Tanaka T; Sano S; Fukuzawa K; Tokumura A
    J Agric Food Chem; 2010 May; 58(10):6053-63. PubMed ID: 20415488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
    Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
    Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
    Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
    J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
    Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
    Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of lysophospholipase D/autotaxin activity in human serum samples.
    Nakamura K; Ohkawa R; Okubo S; Tozuka M; Okada M; Aoki S; Aoki J; Arai H; Ikeda H; Yatomi Y
    Clin Biochem; 2007 Feb; 40(3-4):274-7. PubMed ID: 17222397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
    Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
    Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid is a potential mediator of cholestatic pruritus.
    Kremer AE; Martens JJ; Kulik W; Ruëff F; Kuiper EM; van Buuren HR; van Erpecum KJ; Kondrackiene J; Prieto J; Rust C; Geenes VL; Williamson C; Moolenaar WH; Beuers U; Oude Elferink RP
    Gastroenterology; 2010 Sep; 139(3):1008-18, 1018.e1. PubMed ID: 20546739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
    Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
    ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.